ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Stock Information for ADC Therapeutics SA

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ADC Therapeutics SA

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.